Filing Flows › Tela Bio (TELA) › Q2 2025
Tela Bio (TELA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Tela Bio (TELA) reported revenue of $20.2M for the second quarter 2025 (Q2 2025), +26% from a year earlier and +9% from the quarter before. Operating margin was -45.0%, net loss $9.9M (49.1% of revenue).
Tela Bio, Q2 2025: revenue $20.2M (+26% year over year), operating margin -45.0%, net loss $9.9M, operating cash flow −$7.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.2M | +9% | +26% |
| Operating profit | −$9.1M | — | — |
| Net earnings | −$9.9M | — | — |
| Operating cash flow | −$7.9M | — | — |
What changed
Revenue was $20.2M in Q2 2025, up 26% year over year and up 9% from the previous quarter.
Gross margin was 69.8%, up 1.0 points from a year earlier. Operating costs exceeded revenue by $9.1M, an operating margin of -45.0%. Operating expenses grew 2% against revenue growth of 26%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $9.9M, narrower than the previous quarter's $11.3M loss.
Operating cash flow was −$7.9M. Non-cash charges added back $175K of depreciation and $1.0M of share-based compensation. Working capital and other items added $858K. Capital expenditures of $114K exceeded it, leaving free cash flow of −$8.0M.
Questions
What was Tela Bio's revenue in the second quarter 2025?
Tela Bio (TELA) reported revenue of $20.2M for the second quarter 2025 (Q2 2025), +26% from a year earlier and +9% from the quarter before.
Was Tela Bio profitable in the second quarter 2025?
Operating loss was $9.1M (-45.0% of revenue) and net loss $9.9M.
Source: Tela Bio 10-Q on SEC EDGAR.